



NEXGEL
advanced hydrogel solutions

Investor Presentation

November 2025

Forward-Looking Statement

This presentation contains certain forward-looking statements, including those relating to the Company's product development, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature.

Additional written and oral forward-looking statements may be made by the Company from time to time in filings with the Securities and Exchange Commission (SEC) or otherwise.

The Private Securities Litigation Reform Act of 1995 provides a safe-harbor for forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms.

These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the SEC.

Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this presentation. Except as otherwise required by law, the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

NEXGEL – Who We Are and What We Do

After two decades of creating custom hydrogel solutions for large medical device companies, our business today includes the development of patented medical devices, custom/white label products, and OTC healthcare consumer products.

We invested in our in-house converting and packaging capabilities to better meet our customer's evolving needs.

These strategic growth opportunities reflect our dedication to pioneering advancements across various domains, delivering great value to our customers and stakeholders.

Agreements with Multi-Billion Dollar Corporations



Multiple Products & Applications for Nexgel's Technology

Medical Device

NEXGEL is addressing the importance of skin integrity and overall skincare with a medical device licensing model

Custom & White Label

Bringing proven medical-grade technology to OTC and Beauty & Cosmetics for the first time through many new consumer products & applications

Branded Products

Proprietary consumer brands and accretive M&A opportunities

Competitive Advantage: 1 of 2 State-of-the-Art Manufacturing Facilities in NA

Medical grade technology and facility, providing gels to multi-national device companies for over 20 years with sufficient capacity to fulfill consumer and healthcare segments

1 of 2 manufacturing facilities in North America that can produce state-of-the-art hydrogel transdermal products
– successfully used 200+ different active ingredient combinations to date

16,500-square-ft GMP
13,500-square-ft manufacturing space

3,000-square-ft office space

>1.4 Billion square inches of product per year is total capacity

Sufficient capacity across healthcare and consumer divisions

Electron Beam Accelerator eliminates the need for harmful chemicals in hydrogel production

High barrier to entry for new facilities (2+yrs to go live)

Stringent compliance requirements

Technical expertise needed to operate



Converting and Packaging Facility

50% ownership in converting and packaging business in Granbury, Texas

- Significant synergies which enable the onboarding of potential finished goods customers along with enhanced combined marketing and outreach efforts
- Increased square footage and installed cutting-edge automated machinery in our clean room facilities to support anticipated growth
- CG Labs converting and packaging division is one of NEXGEL's largest customers



Hydrogels for Consumer and Medical Applications

- Electron beam technology eliminates the need for harmful chemicals in cross-linking, which, along with our paraben-free formulation, makes our patches the only option for many medical device applications and preferred among consumers
- Gentle formulation & strong adhesion properties eliminates many problems with existing transdermal devices & dermal interfaces such as:
 - Deterioration of skin integrity
 - Skin allergies
 - Skin irritation
 - Discomfort
 - Skin tears
 - Removal of dermis
 - Pain

All of these contribute to increased risk of infection and overall patient dissatisfaction

Current Medical Device Pipeline

Addressing the importance of skin integrity and overall skincare with a medical device

Medical Device Pipeline: Drug Delivery

Potential for Multiple Drug Delivery Applications through Unique Hydrogel Technology

Drug Delivery: *Diclofenac Patch*


To treat short-term pain due to preclinical sprains and bruises

Drug Delivery: *Apremilast Patch*

To treat autoimmune conditions, such as arthritis and psoriasis

- Promising pre-clinical human results (12 patients)
- Proof-of-concept study completed, validating the potential value of our hydrogel technology for pain indications (arthritis, joint pain, etc.)
- Compared to the current market, NEXGEL's product demonstrated enhanced efficacy (faster-acting, longer lasting, with no mess)

Comparative In-Vitro¹ Human Skin Permeation of Diclofenac Sodium from NEXGEL Patch After 8 Hours



1. In-vitro skin permeation performed using full thickness derma to med human cadaver skin; 250 microns thick in Franz cells (3.65 ml volume with 0.95 cm² surface area) at 37°C. Receptor compartment contained pH 7.4 PBS. 4 cells per formulation sample. Sampling times at 2, 4, and 8 hours. Analysis by HPLC.

2. Skin samples were removed from Franz cell after 8 hours permeation experiment and extracted in ethanol for 12 hours at 37°C. Analysis by HPLC.

Consumer Health & Beauty

Bringing proven medical-grade technology to OTC and B&C for the first time through many new consumer products & applications

NEXGEL Branded Products

NOW PARABEN-FREE



“A little hexagon miracle! I felt immediate relief. I was astounded and will be a customer for life!”
~ Medagel Customer

M&A Strategy: Consumer Brand Acquisition


Kenkoderm Skincare Line

- Acquisition completed in December 2023
- Complimentary line of alternative psoriasis treatments
- Profitable (ttm) and immediately accretive
- 6 SKUs sold primarily DTC with significant portion of revenue derived from subscription bundles



Silly George Beauty Brand

- Acquisition completed in May 2024
- Specialty eye and eyelash consumer product line
- Annual run-rate of \$2mm when purchased, now over \$5mm
- Currently DTC and on Amazon
- Social media following: 89,000 Facebook and 86,000 Instagram followers + 254,000 active customer emails



Synergies support optimization of marketing and supply chain operations to drive revenue growth and margins

New marketing strategies and distribution channels in place to reach a wider consumer base

Cintas Corporation

Cintas is a leading provider of corporate identify uniforms, first aid and safety products and services to over 1 million businesses across North America

- Cintas will distribute SilverSeal, NEXGEL's hospital-grade dressing for wounds and burns to its customers in many sectors including hospitality and public service.
- This wound care solution will be available for employees of their customers.
- Partnership is significant for associated revenue, but also brand recognition awareness among this consumer demographic.
- The initial order of SilverSeal was successfully delivered to Cintas in the fourth quarter of 2024 and has led to additional orders in Q1 '25.

STADA Arzneimittel AG

Partnership with a leading European consumer health company accelerates the expansion of NEXGEL's OTC product portfolio

- STADA, a global leader in consumer healthcare, generics, and specialty pharmaceuticals with sales in ~120 countries, is using this partnership to establish a path into the North American market.
- Strategic, mutually beneficial partnership that enhances NEXGEL's product portfolio and enables distribution and commercialization of STADA's consumer health OTC products.
- Their first joint product is Histasolv (sold as Daosin in Europe), the continent's top-selling DAO enzyme supplement for histamine intolerance, generating over \$20 million in annualized European revenue.
- Histasolv launched in Q3 2024 with strong sales growth; STADA agreed to provide \$1 million in non-dilutive capital to expand the partnership and support new product launches in Q4 2025 and early 2026, including digestive enzyme products for new indications, scar treatments, and stretch mark solutions.

New Partnerships & Customers

Reducing Carcinogenic Plume in Laser Hair Removal

- *An FDA-compliant IRB study conducted by Innovative Optics evaluating NEXGEL hydrogel's efficacy in reducing harmful plume during laser hair removal.*
- *30-patient trial at Florida Clinical Research Center.*
- *Data publication shortly with commercial launch in 2025 upon meeting endpoint of study.*
- *Well over a dozen states have enacted legislation mandating the use of plume evacuation systems in order to mitigate hazards and risks of exposure to plume.*


iRhythm's (NASDAQ: IRTC) ECG Heart Monitor

- *Supply iRhythm with our ultra-gentle, high-moisture hydrogel for integration into the Zio® ECG heart monitor.*
- *Zio is a single-use ECG heart monitor that provides a continuous, single-channel recording for up to 14 days.*
- *Monitor is worn on the upper left chest, & uses NEXGEL's hydrogel wings for secure, comfortable wear and easy removal.*
- *iRhythm's Zio heart monitor showcases another impactful application for our skin-friendly, dermatologically safe technology.*



iRHYTHM

Revenue for Q3 '25



Highlights:

- Q3 2025 Gross Profit: \$1.24 million & profit margin of 42.4% compared to \$1.16 million and 39.2% in Q3 2024.
- Q3 2025 Revenue: \$2.93 million, YoY vs \$2.94 million for Q3 2024.
- As of November 10, 2025, Nexgel had 8,143,133 shares outstanding.
- Expects revenues to increase sequentially and Q4 will be a record quarter for the company.
- Revenue guidance of \$12 to \$12.5 million for 2025 and expect to narrow even further Adjusted EBITDA breakeven for the year.

Contact Us

Investor Relations:

KCSA Strategic Communications

Valter Pinto, Managing Director

PH: (212) 896-1254

NEXGEL@KCSA.com